NCT02873156View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

November 29, 2017

Study Completion Date

November 29, 2017

Conditions
Healthy Subjects
Interventions
DRUG

E2027

Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.

DRUG

E2027 matched placebo

Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.

Trial Locations (1)

91206

California Clinical Trials Medical Group, Glendale

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02873156 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects | Biotech Hunter | Biotech Hunter